Investor Update

Basel, 21 June 2006

FDA approves Avastin in combination with chemotherapy for second-line metastatic colorectal cancer patients

Please find a Genentech news release announcing that the U.S. Food and Drug Administration (FDA) approved Avastin (bevacizumab) in combination with intravenous 5-fluorouracil (5-FU)-based chemotherapy for second-line metastatic colorectal cancer.

Please do not hesitate to contact us if you have any further questions.